Key result
Elevated baseline myeloperoxidase predicts ~310% higher 30-day MACE risk in patients with troponin-negative chest pain.
Why the study?
Does initial plasma myeloperoxidase level predict the risk of major adverse cardiac events in patients presenting to the emergency department with chest pain?
Population
604 sequential patients presenting to the emergency department with chest pain
Design
Cohort
Follow-up
6 months
Authors
Loading...
May aid risk stratification in troponin-negative chest pain; leaves open prospective validation before clinical adoption.
Cohort (n=604)
Does initial plasma myeloperoxidase level predict the risk of major adverse cardiac events in patients presenting to the emergency department with chest pain?
Effect estimate: OR 4.1 (95% CI 2.0-8.4)
p-value: p=<0.001
Initial plasma myeloperoxidase levels independently predict the 30-day and 6-month risk of major adverse cardiac events in patients presenting with chest pain, even when troponin T is negative.
Brennan et al. (2003) conducted a cohort in Chest pain (n=604). Plasma myeloperoxidase vs. 1st quartile of myeloperoxidase was evaluated on Major adverse cardiac events (myocardial infarction, need for revascularization, or death) at 30 days (OR 4.1, 95% CI 2.0-8.4, p=<0.001). Elevated baseline plasma myeloperoxidase independently predicted 30-day major adverse cardiac events in troponin-negative patients presenting with chest pain (4th quartile OR 4.1; 95% CI 2.0-8.4).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: